University of Hertfordshire

From the same journal

By the same authors

Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer

Research output: Contribution to journal › Article › peer-review

Standard

Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer. / Einerhand, Sarah MH; Black, Anna J; Zargar, Homayoun; Fairey, Adrian S.; Dinney, Colin P; Mir, Maria C; Krabbe, Laura-Maria; Cookson, Michael S.; Jacobson, Niels-Erik; Montgomery, Jeffrey S; Vasdev, Nikhil; Yu, Evan Y; Xylinas, Evanguelos; Kassouf, Wassim; Dall’Era, Marc A.; Sridhar, Srikala S.; McGrath, Jonathan S; Aning, Jonathan; Shariat, Shahrokh F; Wright, Jonathan L.; Thorpe, Andrew C.; Morgan, Todd M; Holzbeierlein, Jeff M.; Bivalacqua, Trinity J; North, Scott; Barocas, Daniel A.; Lotan, Yair; Grivas, Petros; Garcia, Jorge A; Stephenson, Andrew J; Shah, Jay B; Daneshmand, Simak; Spiess, P. E.; van Rhijn, Bas W; Black, Peter C.; Mertens, L. S.

In: Journal of Urology, 11.05.2022.

Research output: Contribution to journal › Article › peer-review

Harvard

Einerhand, SMH, Black, AJ, Zargar, H, Fairey, AS, Dinney, CP, Mir, MC, Krabbe, L-M, Cookson, MS, Jacobson, N-E, Montgomery, JS, Vasdev, N, Yu, EY, Xylinas, E, Kassouf, W, Dall’Era, MA, Sridhar, SS, McGrath, JS, Aning, J, Shariat, SF, Wright, JL, Thorpe, AC, Morgan, TM, Holzbeierlein, JM, Bivalacqua, TJ, North, S, Barocas, DA, Lotan, Y, Grivas, P, Garcia, JA, Stephenson, AJ, Shah, JB, Daneshmand, S, Spiess, PE, van Rhijn, BW, Black, PC & Mertens, LS 2022, 'Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer', Journal of Urology.

APA

Einerhand, S. MH., Black, A. J., Zargar, H., Fairey, A. S., Dinney, C. P., Mir, M. C., Krabbe, L-M., Cookson, M. S., Jacobson, N-E., Montgomery, J. S., Vasdev, N., Yu, E. Y., Xylinas, E., Kassouf, W., Dall’Era, M. A., Sridhar, S. S., McGrath, J. S., Aning, J., Shariat, S. F., ... Mertens, L. S. (2022). Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer. Manuscript submitted for publication.

Vancouver

Einerhand SMH, Black AJ, Zargar H, Fairey AS, Dinney CP, Mir MC et al. Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer. Journal of Urology. 2022 May 11.

Author

Einerhand, Sarah MH ; Black, Anna J ; Zargar, Homayoun ; Fairey, Adrian S. ; Dinney, Colin P ; Mir, Maria C ; Krabbe, Laura-Maria ; Cookson, Michael S. ; Jacobson, Niels-Erik ; Montgomery, Jeffrey S ; Vasdev, Nikhil ; Yu, Evan Y ; Xylinas, Evanguelos ; Kassouf, Wassim ; Dall’Era, Marc A. ; Sridhar, Srikala S. ; McGrath, Jonathan S ; Aning, Jonathan ; Shariat, Shahrokh F ; Wright, Jonathan L. ; Thorpe, Andrew C. ; Morgan, Todd M ; Holzbeierlein, Jeff M. ; Bivalacqua, Trinity J ; North, Scott ; Barocas, Daniel A. ; Lotan, Yair ; Grivas, Petros ; Garcia, Jorge A ; Stephenson, Andrew J ; Shah, Jay B ; Daneshmand, Simak ; Spiess, P. E. ; van Rhijn, Bas W ; Black, Peter C. ; Mertens, L. S. / Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer. In: Journal of Urology. 2022.

Bibtex

@article{130fa278cb5f413997107726776792e3,
title = "Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer",
abstract = "Background Preoperative cisplatin-based chemotherapy followed by radical cystectomy (RC) is recommended in patients with muscle-invasive bladder cancer (MIBC). However, up to 50% of patients are cisplatin-ineligible. The aim of the present study was to compare pathological response and survival after at least three cycles of neoadjuvant or induction gemcitabine-carboplatin (gem-carbo) versus gemcitabine-cisplatin (gem-cis) followed by RC in a large, multicenter evaluation. Methods We identified 1865 patients with MIBC who were treated with chemotherapy followed by RC at 19 centers between 2000 and 2013. Patients were included if they had received at least three cycles of neoadjuvant (cT2-4aN0M0) or induction (cTanyN+M0) gem-carbo or gem-cis, followed by RC (n=747). Multivariable analyses were performed to determine factors predictive of pathological response at RC and survival. Results Of the included patients, 147 were pre-treated with gem-carbo and 600 with gem-cis. Patients treated with gem-carbo were significantly older (67 vs 65 years; P<0.001), had a higher Charlson Comorbidity Index (P=0.016) and more often had clinically node-positive disease (32% vs 20%; p=0.013). The complete pathological response (pCR; ypT0N0) rate did not significantly differ after gem-carbo versus gem-cis (20.7% versus 22.1%; p=0.73). Median follow-up was 14.3 months. In multivariable analyses, chemotherapeutic regimen was not statistically significantly associated with pCR (OR: 0.99 [95%CI, 0.61-1.59]; p=0.96), overall survival (HR: 1.20 [95% CI, 0.85-1.67]; p=0.31), or cancer-specific survival (HR: 1.35 [95% CI, 0.93-1.96]; p=0.11). Subanalyses (neoadjuvant and induction setting) also did not show significant survival differences between patients treated with gem-carbo vs gem-cis.Conclusion Results from this multicenter study show that a subset of cisplatin-ineligible patients with MIBC achieve pathological response to gem-carbo at RC, and that survival outcomes seem comparable to gem-cis in the neoadjuvant and induction setting provided patients are able to receive at least three cycles and undergo RC.",
author = "Einerhand, {Sarah MH} and Black, {Anna J} and Homayoun Zargar and Fairey, {Adrian S.} and Dinney, {Colin P} and Mir, {Maria C} and Laura-Maria Krabbe and Cookson, {Michael S.} and Niels-Erik Jacobson and Montgomery, {Jeffrey S} and Nikhil Vasdev and Yu, {Evan Y} and Evanguelos Xylinas and Wassim Kassouf and Dall{\textquoteright}Era, {Marc A.} and Sridhar, {Srikala S.} and McGrath, {Jonathan S} and Jonathan Aning and Shariat, {Shahrokh F} and Wright, {Jonathan L.} and Thorpe, {Andrew C.} and Morgan, {Todd M} and Holzbeierlein, {Jeff M.} and Bivalacqua, {Trinity J} and Scott North and Barocas, {Daniel A.} and Yair Lotan and Petros Grivas and Garcia, {Jorge A} and Stephenson, {Andrew J} and Shah, {Jay B} and Simak Daneshmand and Spiess, {P. E.} and {van Rhijn}, {Bas W} and Black, {Peter C.} and Mertens, {L. S.}",
year = "2022",
month = may,
day = "11",
language = "English",
journal = "Journal of Urology",

}

RIS

TY - JOUR

T1 - Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer

AU - Einerhand, Sarah MH

AU - Black, Anna J

AU - Zargar, Homayoun

AU - Fairey, Adrian S.

AU - Dinney, Colin P

AU - Mir, Maria C

AU - Krabbe, Laura-Maria

AU - Cookson, Michael S.

AU - Jacobson, Niels-Erik

AU - Montgomery, Jeffrey S

AU - Vasdev, Nikhil

AU - Yu, Evan Y

AU - Xylinas, Evanguelos

AU - Kassouf, Wassim

AU - Dall’Era, Marc A.

AU - Sridhar, Srikala S.

AU - McGrath, Jonathan S

AU - Aning, Jonathan

AU - Shariat, Shahrokh F

AU - Wright, Jonathan L.

AU - Thorpe, Andrew C.

AU - Morgan, Todd M

AU - Holzbeierlein, Jeff M.

AU - Bivalacqua, Trinity J

AU - North, Scott

AU - Barocas, Daniel A.

AU - Lotan, Yair

AU - Grivas, Petros

AU - Garcia, Jorge A

AU - Stephenson, Andrew J

AU - Shah, Jay B

AU - Daneshmand, Simak

AU - Spiess, P. E.

AU - van Rhijn, Bas W

AU - Black, Peter C.

AU - Mertens, L. S.

PY - 2022/5/11

Y1 - 2022/5/11

N2 - Background Preoperative cisplatin-based chemotherapy followed by radical cystectomy (RC) is recommended in patients with muscle-invasive bladder cancer (MIBC). However, up to 50% of patients are cisplatin-ineligible. The aim of the present study was to compare pathological response and survival after at least three cycles of neoadjuvant or induction gemcitabine-carboplatin (gem-carbo) versus gemcitabine-cisplatin (gem-cis) followed by RC in a large, multicenter evaluation. Methods We identified 1865 patients with MIBC who were treated with chemotherapy followed by RC at 19 centers between 2000 and 2013. Patients were included if they had received at least three cycles of neoadjuvant (cT2-4aN0M0) or induction (cTanyN+M0) gem-carbo or gem-cis, followed by RC (n=747). Multivariable analyses were performed to determine factors predictive of pathological response at RC and survival. Results Of the included patients, 147 were pre-treated with gem-carbo and 600 with gem-cis. Patients treated with gem-carbo were significantly older (67 vs 65 years; P<0.001), had a higher Charlson Comorbidity Index (P=0.016) and more often had clinically node-positive disease (32% vs 20%; p=0.013). The complete pathological response (pCR; ypT0N0) rate did not significantly differ after gem-carbo versus gem-cis (20.7% versus 22.1%; p=0.73). Median follow-up was 14.3 months. In multivariable analyses, chemotherapeutic regimen was not statistically significantly associated with pCR (OR: 0.99 [95%CI, 0.61-1.59]; p=0.96), overall survival (HR: 1.20 [95% CI, 0.85-1.67]; p=0.31), or cancer-specific survival (HR: 1.35 [95% CI, 0.93-1.96]; p=0.11). Subanalyses (neoadjuvant and induction setting) also did not show significant survival differences between patients treated with gem-carbo vs gem-cis.Conclusion Results from this multicenter study show that a subset of cisplatin-ineligible patients with MIBC achieve pathological response to gem-carbo at RC, and that survival outcomes seem comparable to gem-cis in the neoadjuvant and induction setting provided patients are able to receive at least three cycles and undergo RC.

AB - Background Preoperative cisplatin-based chemotherapy followed by radical cystectomy (RC) is recommended in patients with muscle-invasive bladder cancer (MIBC). However, up to 50% of patients are cisplatin-ineligible. The aim of the present study was to compare pathological response and survival after at least three cycles of neoadjuvant or induction gemcitabine-carboplatin (gem-carbo) versus gemcitabine-cisplatin (gem-cis) followed by RC in a large, multicenter evaluation. Methods We identified 1865 patients with MIBC who were treated with chemotherapy followed by RC at 19 centers between 2000 and 2013. Patients were included if they had received at least three cycles of neoadjuvant (cT2-4aN0M0) or induction (cTanyN+M0) gem-carbo or gem-cis, followed by RC (n=747). Multivariable analyses were performed to determine factors predictive of pathological response at RC and survival. Results Of the included patients, 147 were pre-treated with gem-carbo and 600 with gem-cis. Patients treated with gem-carbo were significantly older (67 vs 65 years; P<0.001), had a higher Charlson Comorbidity Index (P=0.016) and more often had clinically node-positive disease (32% vs 20%; p=0.013). The complete pathological response (pCR; ypT0N0) rate did not significantly differ after gem-carbo versus gem-cis (20.7% versus 22.1%; p=0.73). Median follow-up was 14.3 months. In multivariable analyses, chemotherapeutic regimen was not statistically significantly associated with pCR (OR: 0.99 [95%CI, 0.61-1.59]; p=0.96), overall survival (HR: 1.20 [95% CI, 0.85-1.67]; p=0.31), or cancer-specific survival (HR: 1.35 [95% CI, 0.93-1.96]; p=0.11). Subanalyses (neoadjuvant and induction setting) also did not show significant survival differences between patients treated with gem-carbo vs gem-cis.Conclusion Results from this multicenter study show that a subset of cisplatin-ineligible patients with MIBC achieve pathological response to gem-carbo at RC, and that survival outcomes seem comparable to gem-cis in the neoadjuvant and induction setting provided patients are able to receive at least three cycles and undergo RC.

M3 - Article

JO - Journal of Urology

JF - Journal of Urology

ER -